RYVU THERAPEUTICS S.A.
Q1 2024 Report

TABLE OF CONTENTS

1. ECONOMIC AND FINANCIAL HIGHLIGHTS

1.1 Financial Results Obtained in the Reporting Period

Condensed Interim Financial Statements of Ryvu Therapeutics S.A. ("Company", "Issuer", "Ryvu") for the period from January 1, 2024 to March 31, 2024 are prepared in accordance with the requirements of the International Accounting Standard No. 34 "Interim Financial Reporting" endorsed by the EU ("IAS 34").

Selected data of statement of financial position are as follows:

Ryvu Therapeutics S.A.	Data in PLN thousand		Data in EUR thousand	
Item	**31.03.2024**	31.12.2023	**31.03.2024**	31.12.2023
Total assets	**404,835**	403,202	**94,128**	92,733
Short-term receivables	**35,309**	32,837	**8,210**	7,552
Cash and cash equivalents	**129,719**	57,939	**30,161**	13,325
Other financial assets	**121,109**	193,213	**28,159**	44,437
Total liabilities	**209,524**	143,610	**48,716**	33,029
Long-term liabilities	**147,589**	73,907	**34,316**	16,998
Short-term liabilities	**61,934**	69,703	**14,400**	16,031
Total equity	**195,311**	259,592	**45,412**	59,704
Share capital	**9,248**	9,248	**2,150**	2,127

Selected data of statement of comprehensive income are as follows:

Ryvu Therapeutics S.A.	Data in PLN thousand		Data in EUR thousand	
Item	**From 01.01.2024 to 31.03.2024**	From 01.01.2023 to 31.03.2023	**From 01.01.2024 to 31.03.2024**	From 01.01.2023 to 31.03.2023
Revenues from sales	**10,164**	5,012	**2,352**	1,066
Revenues from subsidies	**3,820**	5,455	**884**	1,161
Revenues from R&D projects	**11,442**	7,849	**2,648**	1,670
Other operating revenues	**76**	238	**18**	51
Revenues from operating activities	**25,503**	18,554	**5,902**	3,947
Operating expenses	**-47,974**	-36,657	**-11,102**	-7,799
Operating expenses without Incentive Scheme and valuation of Nodthera shares	**-46,750**	-32,883	**-10,819**	-6,996
Depreciation	**-2,762**	-2,782	**-639**	-592
Valuation of Incentive Scheme	**-1,207**	-2,991	**-279**	-636
Loss from operating activities (EBIT)	**-22,471**	-18,103	**-5,200**	-3,851
Loss from operating activities (EBIT) without Incentive Scheme and valuation of Nodthera shares	**-21,247**	-14,329	**-4,917**	-3,048
Loss before income tax	**-19,376**	-17,597	**-4,484**	-3,744
Net loss	**-19,399**	-17,597	**-4,489**	-3,744
Net loss without Incentive Scheme	**-18,192**	-14,606	**-4,210**	-3,107
EBITDA	**-19,709**	-15,321	**-4,561**	-3,259
EBITDA without Incentive Scheme and valuation of Nodthera shares	**-18,485**	-11,547	**-4,278**	-2,457
Net cash flows from operating activities	**-43,235**	-33,268	**-10,006**	-7,078
Net cash flows from investing activities	**76,974**	-11,358	**17,814**	-2,416
Net cash flows from financing activities	**33,901**	241,549	**7,845**	51,388
Total net cash flow	**67,640**	196,923	**15,653**	41,894
Number of shares (weighted average)	**23,120,148**	22,220,154	**23,120,148**	22,220,154
Profit (loss) per share (in PLN)	**-0.84**	-0.79	**-0.19**	-0.17
Diluted profit (loss) per share (in PLN)	**-0.84**	-0.79	**-0.19**	-0.17
Book value per share (in PLN)	**8.45**	14.80	**1.96**	3,16
Diluted book value per share (in PLN)	**8.45**	14.80	**1.96**	3,16
Declared or paid dividend per share (in PLN)	**-**	-	**-**	-

Selected financial data presented in the quarterly report were converted to Euro as follows:

1. Items relating to the profit and loss statement and the cash flow statement were converted using the exchange rate constituting the arithmetic average of the exchange rates, applicable as of the last day of every month in the given period, based on the information published by the National Bank of Poland (NBP):
   - for the period from 01/01/2024 – 31/03/2024: PLN 4.3211;
   - for the period from 01/01/2023 – 31/03/2023: PLN 4.7005;
2. Balance sheet items were converted using the average exchange rate announced by the NBP applicable as of the balance sheet date, which were:
   - as of 31 March 2024: PLN 4.3009;
   - as of 31 December 2023: PLN 4.3480

1.2 Management Board comments to the financial results

In the first quarter of 2024, Ryvu Therapeutics S.A. recognized total operating revenue of PLN 25,503 thousand, which constitutes an increase compared to the corresponding period in 2023, when total operating revenue amounted to PLN 18,554 thousand. This results from an increase in revenues from sales (an increase of PLN 5,152 thousand) and increase in revenues from R&D projects (an increase of PLN 3,593 thousand) partially compensated by a decrease in revenues from subsidies (a decrease of PLN 1,635 thousand) compared to the corresponding period in 2023.

The increase of revenues from sales resulted mostly from research collaboration with BioNTech SE. Under the License Agreement, Ryvu provides appropriately qualified employees and BioNTech funds all discovery, research and development activities under the multi-target research collaboration.

Revenues from R&D projects in the first quarter of 2024 resulted from the following transactions:

- achievement of a milestone and payment in the amount of USD 2 million on the basis of the exclusive license agreement with Exelixis Inc. The agreement combines Ryvu's proprietary small molecule STING agonists and STING biology know-how with Exelixis' network of expertise and resources in antibody engineering, antibody-drug conjugate (ADC) technologies, and oncology therapeutics development and commercialization experience.
- recognition of a portion of the upfront payment in the amount of PLN 3,514 thousand from the exclusive research collaboration and license agreement with BioNTech SE. In accordance with the accounting policy of Ryvu and IFRS 15, in 2022 Ryvu recognized only a part of the upfront revenues. The remaining amount is recognized equally in each period for 5 years.

In the first quarter of 2024, Ryvu reported a net loss, as well as an operating loss. The net and operating losses are the result of the fact that the Company focuses on increasing the value of the ongoing projects that will be commercialized at a later stage of development.

The Company's net loss for the period ended March 31, 2024, amounted to PLN 19,399 thousand compared to the net loss of PLN 17,597 thousand in the corresponding period of 2023. The higher loss in first quarter of 2024 in comparison to corresponding period in 2023, is related to higher expenditures incurred on discovery and clinical development projects, partially compensated by a lower negative impact of incentive program for its employees of PLN 1,207 thousand (described below) and lower negative impact in NodThera shares valuation of PLN 17 thousand (described below).

Valuation of shares in NodThera Inc.

Valuation of shares

As of March 31, 2024, four types of shares existed in NodThera Inc.: ordinary stock and preferred stock (Junior Preferred Stock, Series A1 and A2 Preferred Stock, Series B Preferred Stock and Series C Preferred Stock). Ryvu is a holder of the Junior Preferred Stock.

Associated with the Series A, B and C Preferred Stock is the right to receive dividends in the form of cash or the issuance of shares of the same class and the non-dilution right. The payment of dividends and execution of the anti-dilution right may be made only in cases specified in the investment agreement, in particular in the event of a sale of the company or the admission of its shares to trading on a stock exchange. The shares held by Ryvu, i.e. Junior Preferred Stock, do not have the aforementioned right to pay dividends or the non-dilution right.

Series C Preferred Stock was issued by NodThera Inc. on September 20, 2022. The issue comprised of 8,698,375 shares at a price of USD 2.8741 per share. As a result of this issue, NodThera received financing in the total amount of USD 25,000,002.47. The issue was addressed only to existing investors. Ryvu did not participate in the issue.

On November 7, 2023, the shareholders of Nodthera Inc. passed a resolution enabling company to issue up to USD 20 million in aggregate of convertible promissory notes and warrants. Ryvu chose not to participate in this financing.

Thanks to the receipt of funds raised from the Series C share issue and the aforementioned financing, according to information obtained from NodThera Inc., NodThera has the necessary financial resources to implement the projects currently underway.

The Management Board of Ryvu has decided to include in the valuation of the shares held by Ryvu in NodThera, a 20.05% discount (reflecting no right to dividend and non-dilution right) to the price at which they were subscribed under the last share capital increase, i.e. issuance of series C on September 20, 2022, and the above approach was applied as of March 31, 2024. The discount applied in the valuation as of December 31, 2023, was 18.73%.

Therefore, a share valuation of USD 2.2165/share (share price from the last financing round from September 20, 2022, including a discount corresponding to the class of shares held by the Issuer and last convertible notes and warrants financing) should be used as a basis for the calculations. As of March 31, 2024, Ryvu held 2.38% shares in NodThera on a fully diluted basis, and the total valuation of the Issuer's shares in NodThera Inc. amounts to PLN 16,886,057 (at the average NBP exchange rate of 3.9886 PLN/USD).

Valuation of shares in NodThera Inc. according to fair value:

new share issue price (in USD)	2.2165
average NBP exchange rate from March 31, 2024	3.9886
new share issue price (in PLN)	8.8500
number of the Company's shares in NodThera Inc.	1,910,000
value of shares in the balance sheet as of March 31, 2024	**16,886,057**
value of shares in the balance sheet as of December 31, 2023	16,903,500
change in valuation – gross impact on the valuation of shares	**-17,443**

Incentive Scheme

On May 17, 2021, the General Shareholders Meeting adopted the non-dilutive Stock Grant Program for 2021-2024 for all employees in the form of the right to acquire shares of the Company. The Stock Grant Program is comprised of 1,247,720 ordinary shares of the Company that have been donated free of charge by Mr. Paweł Przewięźlikowski – founder, President of the Management Board, and Company's largest shareholder to the Company, constituting a total of 25% of the Company's shares held by Mr. Paweł Przewięźlikowski. The Stock Grant Program provides employees with the right to acquire shares at a preferential price of PLN 0.19 per share, covering the Company's

administrative costs incurred to execute the Stock Grant Program. The fair value of the shares granted is determined as of the grant date and recognized over the vesting period in remuneration costs in correspondence with the capital increase at the time of vesting by employees during the program. For the period ending March 31, 2024, the Company recognized the non-cash cost of valuation of this incentive program of PLN 1,207 thousand – more details are described in note 21 to the financial statements.

Disbursement of the Tranche A of financing from the European Investment Bank

On March 13, 2024, the European Investment Bank (EIB) made a payment of Tranche A of financing in the amount of EUR 8.0 million. The funding from the disbursed tranche is recorded in the Company's financial statement as a financial liability (under bank loans) measured at amortized cost. On each reporting date, the Company determines the carrying amount (amortized cost) of the liability by applying the effective interest rate method, according to which the interest cost for the period is calculated.

The subscription warrants issued by the Company in connection with the financing obtained under Tranche A (215,575 warrants) were recognized in equity at the time of the disbursement of this tranche, as the difference between the amount of funds received from the European Investment Bank (EIB) by the Company and the initial fair value of the financial liability. Transaction costs directly related to the issuance of warrants have been recognized in equity.

Additionally, because the put option issued by the Company creates a contractual obligation to repurchase its own equity instruments (warrants), on the day of the disbursement of Tranche A, the Company recognized a liability for the amount required to settle the option in accordance with IAS 32, offset against equity. On each reporting date after the initial recognition, the Company updates the amount of the liability for the put option, taking into account changes in the settlement price of this option, with the effects of the valuation reflected in the statement of comprehensive income. If the put option expires without being exercised by the holder (European Investment Bank), the Company will reclassify the carrying value of the liability to equity.

1.3 The Company's Assets and the Structure of Assets and Liabilities

As of March 31, 2024, the value of the Company's assets was PLN 404,835 thousand and increased by PLN 1,633 thousand compared to the end of 2023 (PLN 403,202 thousand), mainly due to the disbursement of tranche A from the European Investment Bank of EUR 8.0 million compensated by expenditures on R&D projects (described above). At the end of March 2024, the highest value of assets was cash, which amounted to PLN 129,719 thousand (at the end of 2023, it was PLN 57,939 thousand) and other financial assets of PLN 121,109 thousand (at the end of 2024, it was PLN 193,213 thousand). The slight decrease in cash and other financial assets resulted mainly from expenditures incurred on discovery and clinical development projects compensated by the above-mentioned disbursement of tranche A. Fixed assets are mainly the Research and Development Centre for Innovative Drugs (named 'CBR') and laboratory equipment, as well as the valuation of NodThera shares of PLN 16,886 thousand.

The main item in Ryvu's equity and liabilities is equity, which amounted to PLN 195,312 thousand as of March 31, 2024, and decreased by PLN 64,280 thousand compared to December 31, 2023. The decrease in equity is primarily attributable to the above-mentioned recognition of the put option and

warrants issued, as well as the net loss recorded for the period. The other source of assets' funding are long-term liabilities, which amounted to PLN 147,589 thousand at the end of March 2024. The long-term liabilities are mainly related to the loan received from the European Investment Bank and associated recognition of the put option. Additionally, long-term liabilities include deferred income, largely related to deferred revenue from the BioNTech agreement, and the infrastructure subsidy for CBR.

The asset structure demonstrates the Company's high financial liquidity, which is confirmed by the following ratios:

	31.03.2024	31.12.2023
Current ratio current assets/current liabilities, including short-term provisions and accruals (excl. deferred revenues)	5.27	4.39
Quick ratio (current assets-inventory)/current liabilities, including short-term provisions and accruals (excl. deferred revenues)	5.24	4.35

Cash surpluses, not used in the operating activities, are deposited in low-risk financial instruments like short term bank deposits and bonds.

1.4 Current and Projected Financial Condition

The Company's financial position as of the report date is very good, considering the current cash position and the expected financing from the European Investment Bank (tranches B and C). As of March 31, 2024, the value of the Company's cash amounted to PLN 250,281 thousand (PLN 240,455 thousand in cash at the banks and PLN 9,826 thousand in bonds), and as of May 9, 2024, it was PLN 236,356 thousand (PLN 226,441 thousand in cash at the banks and PLN 9,915 thousand in bonds). The decrease in cash resulted from expenditure incurred on early pipeline and clinical development projects.

The Company meets its obligations in a timely manner and maintains sustainable cash levels, ensuring its financial liquidity. Cash inflow from previous share issues, funds obtained from subsidies from the EU, funds supporting R&D projects and cash generated from the commercialization of projects allow the Company to execute its planned investments, particularly the development of ongoing and new innovative projects and expansion of laboratory infrastructure. The Company's future revenues will strongly depend on the ability to commercialize its R&D projects.

2 MANAGEMENT BOARD INFORMATION ON ACTIVITES

2.1 The pipeline

Ryvu Therapeutics is advancing a broad pipeline addressing emerging targets in oncology.

Ryvu's pipeline includes candidates with differentiated therapeutic mechanisms, including programs directed at kinases, synthetic lethality, immuno-oncology and immunometabolism pathways. These research and development projects are represented below.



Source: Company's own data.

RVU120 (SEL120)

RVU120 (also known as SEL120) is a clinical-stage, selective, first-in-class dual inhibitor of CDK8 and CDK19 kinases. RVU120 has demonstrated efficacy in a number of solid tumors and hematologic malignancies in *in vitro* and *in vivo* models. CDK8 and its paralog CDK19 are kinase submodules of the mediator complex, involved in both transcriptional activation and repression, having central roles in the maintenance of cancer cell viability and undifferentiated state for a variety of tumor types (Dannappel et al. 2019; Rzymski et al. 2015; Philip et al. 2018). CDK8/19-mediator complex integrates basal transcriptional machinery with the activity of oncogenic transcriptional and epigenetic factors. Inhibition of CDK8/19 can repress key oncogenic transcriptional programs and induce lineage commitment genes in acute myeloid leukemia (AML).

RVU120 was internally discovered by Ryvu and has received support from the Leukemia & Lymphoma Society Therapy Acceleration Program® (TAP), a strategic initiative to partner directly with innovative biotechnology companies and leading research institutions to accelerate the development of promising new therapies for blood cancers.

On March 25, 2020, the U.S. Food and Drug Administration (FDA) granted RVU120 an orphan drug designation (ODD) for the treatment of patients with AML.

Two clinical Phase I studies with RVU120 are still ongoing: (i) Phase Ib in patients with AML/HR-MDS (NCT04021368, RIVER-51) and (ii) Phase I/II in patients with relapsed/refractory metastatic or advanced solid tumors (NCT05052255, AMNYS-51).

Preliminary data of the dose escalation part of AMNYS-51 were presented at the ESMO Conference in October 2023. Findings confirmed the favorable safety profile of RVU120 in a heavily pretreated, unselected patient population. No dose-limiting toxicities or other safety signals were observed.

The latest update of the RIVER-51 clinical study was presented at the 65th ASH Annual Meeting and Exposition in December 2023 in San Diego. Data showed that doses up to 250 mg have been tolerated in patients with AML or HR-MDS with a target engagement level of 50%-70%. This level is predicted to result in robust antileukemic efficacy in selected populations and combinations based on preclinical data. Identifying a therapeutic window confirms CDK8/19 inhibition as a viable approach for cancer therapies. RVU120 as a single agent showed signs of clinical activity in 14 out of 28 evaluable patients (50%). This includes a complete response, a morphologic leukemia-free state, and several patients with blast reductions, hematologic improvement, or reduction of bone marrow fibrosis. In particular, early signs of efficacy were observed in patients with NPM1 mutation, DNMT3a mutation, and in patients with HR-MDS.

Considering the currently available translational and clinical data, Ryvu is executing a development plan that includes four Phase II studies. The focus of the clinical development plan will be on hematologic malignancies. While translational research is ongoing to determine the opportunities for RVU120 in solid tumors, a clinical study in patients with specific solid tumors is not yet planned.

On January 31, 2024, Ryvu announced the dosing of the first patient in the RIVER-81 Phase II study of RVU120 in combination with venetoclax (NCT06191263). RIVER-81 is a multicenter, open-label clinical trial that aims to assess the safety, tolerability, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of RVU120 when administered in combination with venetoclax to patients with AML who are relapsed or refractory to prior therapy with venetoclax and a hypomethylating agent. This study initially launched at clinical sites in Poland and Italy. Ultimately, the study will expand to other EU and non-EU countries, covering up to 50 clinical sites globally. The planned overall enrollment for the study is up to approx. 98 patients. Execution of the RIVER-81 study is supported by a PLN 62.3 million grant from the Polish Medical Research Agency (ABM).

The first patient in the RIVER-52 Phase II study was dosed on February 14, 2024. RIVER-52 is a multicenter, open-label clinical trial designed to assess the safety, tolerability, anti-tumor activity (efficacy), pharmacokinetics (PK), and pharmacodynamics (PD) of RVU120 as a monotherapy in patients with genetically defined subtypes of AML including NPM1 and DNMT3a mutations, as well as with HR-MDS without alternative treatment options. The planned overall enrollment is up to approximately 140 patients, and the study will be conducted at up to 80 clinical sites globally.

RIVER-81 and RIVER-52 are part of RVU120's Development Plan presented in October 2023 and align with the company's cash runway to Q1 2026. As part of that Development Plan, two additional Phase II studies will begin in 2024: REMARK and POTAMI-61. The Phase II REMARK study (NCT06243458) will be conducted as an investigator-initiated trial with Prof. Uwe Platzbecker within the European Myelodysplastic Neoplasms Cooperative Group (EMSCO) and will explore RVU120 as a monotherapy

for the treatment of patients with low-risk myelodysplastic syndromes (LR-MDS). The Phase II POTAMI-61 study will investigate RVU120 as a monotherapy and a combination therapy for treating patients with myelofibrosis (MF). RVU120's potential in myelofibrosis is supported by its effect on bone marrow and hematopoietic cells observed in the clinical trial setting as well as translational data generated with Prof. Rajit Rampal at the Memorial Sloan Kettering Cancer Centre as part of a collaboration with Ryvu established in 2021.

Ryvu plans to enroll over 100 patients across all four Phase II studies by the end of 2024. Based on the study outcomes, Ryvu aims to prioritize further development options in Q1 2025. Clinical trials conducted in various hematological indications and treatment regimens (monotherapy and combination therapy) will contribute to the RVU120 safety database, supporting potential future regulatory approvals.

Additionally, multiple translational research activities are underway, aimed at further confirmation of RVU120's mechanism of action, defining the target patient population, identifying potential combination partners, and validating RVU120 in other hemato-oncology as well as solid tumor indications, including combination studies and academic collaborations on medulloblastoma and sarcoma. In April, at the 2024 AACR Annual Meeting in San Diego, California, two academic groups from the Memorial Sloan Kettering Cancer Center and the Dana Faber Cancer Institute presented new preclinical data demonstrating the potential of RVU120 for the treatment of myelofibrosis and rhabdomyosarcoma.

SEL24 (MEN1703)

SEL24 (also known as MEN1703) is a selective, small molecule, dual inhibitor of PIM and FLT3 kinases, two enzymes strongly implicated in the malignant transformation of hematopoietic cells. The compound was discovered by Ryvu and is currently in clinical development in collaboration with Menarini Group as a therapeutic option for various cancers. The licensing contract with Menarini was executed in March 2017, and Menarini is the sole sponsor of the recently completed Phase I/II clinical study. Details of this study can be found at ClinicalTrials.gov under the identifier NCT03008187. Ryvu has also been supporting this project with translational research.

Based on a decision announced in September 2023, Menarini will continue the development of SEL24 (MEN1703) by initiating a new Phase II study in relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Translational work in other hematologic indications will also continue. Menarini will fully fund all study activities, but Ryvu will increase its involvement in the program by becoming the operational partner to execute the planned Phase II study on behalf of Menarini. The licensing partnership with Menarini, including the total milestones and royalties due to Ryvu upon the achievement of certain events, remains unchanged. The Phase II study will explore the activity of SEL24 (MEN1703) in combination with standard-of-care therapy in DLBCL and as a single agent. The study is being initiated based on the strong preclinical activity of SEL24 (MEN1703) in lymphoma.

In April 2024, at the AACR Annual Meeting in San Diego, California, Menarini presented preclinical data for SEL24 (MEN1703) project that shows cytotoxic activity in myelofibrosis cell lines as a monotherapy and synergistically in combination with ruxolitinib.

PRECLINICAL AND DISCOVERY STAGE PROJECTS

Synthetic lethality projects

Ryvu is actively involved in multiple early-stage projects in synthetic lethality. The lead project in this area is the PRMT5 program, which targets cancers characterized by the deletion of the MTAP metabolic gene, a phenomenon observed in approximately 10 to 15% of all human tumors. This deletion leads to a substantial methylthioadenosine (MTA) build-up within cells. At high concentrations, MTA acts as a highly selective inhibitor of the PRMT5 methyltransferase, specifically competing with its substrate, S-adenosylmethionine (SAM). In cells affected by MTAP deletion, the accumulation of MTA results in a partial inhibition of PRMT5's methylation function. This inhibition consequently reduces the level of symmetric dimethylation of arginine across the proteome, heightening the cells' susceptibility to alterations in methylosome activity. Ryvu's strategic approach involves developing MTA-cooperative PRMT5 inhibitors that selectively impede the growth of cancer cells with MTAP deletions.

In Q1 2024, Ryvu continued optimization of the lead series towards the identification of a preclinical candidate. Experimental work aimed to improve the properties of the chemical series was focused on potency, selectivity (measured by the inhibition of SDMA in MTAP-deleted versus MTAP WT cells), and particularly PK parameters in rodent species (necessary for pharmacological and toxicological characterization). For multiple compounds in the series, selectivity for MTAP-deleted cells over WT cells exceeds over 100-fold, both in SDMA and growth inhibition models. Selected Ryvu PRMT5 inhibitors showed robust antiproliferative effects on MTAP-deleted cell lines, providing a good safety window for MTAP WT cells, as shown in a wider cell line panel. Novel Ryvu compounds are characterized by a significantly improved PK profile that allows for oral administration. Optimization allowed the selection of new, improved derivatives for larger-scale synthesis and subsequent PK/PD and efficacy studies in tumor-bearing mice. The correlation between compound exposure and the on-target effect was confirmed in PK/PD and efficacy studies in two MTAP-deleted tumor models. Moreover, in vitro safety evaluations revealed no significant liabilities of the compounds tested. Taken together, these studies support the therapeutic potential of the series.

Data on the Company's MTA-cooperative PRMT5 inhibitors, including a summary of the optimization progress together with *in vivo* results in a mouse model showing tumor growth inhibition and pharmacodynamic biomarkers in MTAP-deleted tumors, were presented at the annual AACR American Association for Cancer Research conference in San Diego, United States in April 2024.

The second disclosed project in the synthetic lethality portfolio aims to discover and create best-in-class, small-molecule chemical inhibitors targeting Werner's helicase (WRN). This helicase plays a key role in cellular processes such as cell proliferation, replicative stress response and DNA repair. Loss of repair function of unpaired DNA fragments is frequently observed in the early stages of cancer development, accounting for 10-30% of endometrial, colorectal, ovarian, and gastric cancers.

WRN helicase inhibitors induce DNA double-strand breaks (DSBs), leading to apoptosis and cell cycle arrest in MSI-H cell lines. This specificity underscores the therapeutic potential of WRN inhibitors, as they show efficacy against microsatellite-unstable MSI-H cancer cells while remaining non-toxic to microsatellite-stable (MSS) cells.

Ryvu's drug chemistry development strategy is anchored in the detailed analysis of the structure-activity relationship (SAR) and the structure-pharmacokinetics relationship (SPR). Our primary

objective is to identify and develop compounds that demonstrate superior efficacy and properties in vitro and in vivo. This strategic approach has successfully led to the creation of derivatives that exhibit increased cellular activity *in vitro* in MSI-H cell line models and are also efficacious *in vivo*. Additionally, Ryvu conducted tests on the lead compound to evaluate its safety and selectivity, confirming that the lead molecule possesses an optimal safety profile.

Data on the Company's WRN inhibitors, including lead molecules with *in vivo* data, were presented at the annual AACR American Association for Cancer Research conference in San Diego, United States, in April 2024.

New, undisclosed targets and target discovery

In addition to the two disclosed projects targeting PRMT5 and WRN, Ryvu is currently running several internal initiatives focused on identifying and validating new targets in synthetic lethality, with potential for first-in-class drug discovery. Work is currently underway to progress those early-stage projects to more advanced stages of hit identification and hit-to-lead phase. Ryvu's proprietary ONCO Prime discovery platform, which recently received a PLN 26 million (approximately USD 6.6 million) grant from the Polish Agency for Enterprise Development, has identified novel drug targets in KRAS-mutant patient-derived cells (PDCs) with therapeutic potential in colorectal cancer; the ONCO Prime platform has broad potential across multiple tumor types. Ryvu's cutting-edge drug discovery platform uniquely combines high throughput capabilities with the precision and translational impact traditionally associated with later, lower throughput stages. By leveraging human stem cell-derived model cells (PDC), patient-derived xenografts (PDXs) and clinical samples, Ryvu created a groundbreaking approach to identifying synthetic lethal (SL) targets specific to oncogenic pathways. Progress and selected data from the Ryvu target discovery platform were also presented at the AARC conference in San Diego, United States, in April 2024.

Collaboration with BioNTech on Immunotherapy and STING

In November 2022, BioNTech and Ryvu embarked on a comprehensive, multi-target research collaboration to advance small molecule programs focused on immune modulation in cancer and potentially other disease areas, based on targets selected by BioNTech. Under this partnership, BioNTech has the right to acquire global development and commercialization rights for these programs. While multiple research initiatives are underway as part of this collaboration, detailed information about these programs remains confidential.

Furthermore, as part of this collaboration, under the license agreement, BioNTech was granted exclusive rights for of a range of small-molecule STING agonists originally discovered and developed by Ryvu. Within the framework of this collaboration, a selected molecule undergoes further preclinical development stages. The progress of the project is confidential.

STING agonist ADC collaboration with Exelixis

In July 2022, Ryvu signed a licensing agreement with Exelixis to develop novel targeted therapies based on the advanced STING agonist technology worked out at Ryvu. During the optimization work, opportunities were discovered for molecular structure modifications that enable the combination with reactive chemical groups, allowing the formation of antibody-drug conjugates (ADCs). The appropriately selected antibody will be a carrier for the STING protein agonist.

The second milestone was reached in February 2024, which, according to the agreement, entitled Ryvu to receive a $2 million payment from Exelixis. Further progress on the project remains confidential.

2.2 Significant events in Q1 2024

A) DURING THE REPORTING PERIOD

Resignation of a member of the Company's Supervisory Board from his position

On January 3, 2024, the Company received a statement of resignation of Mr. Jarl Ulf Jungnelius from his position as a member of the Company's Supervisory Board, effective immediately, without stating the reason thereof.

Take-up of series K subscription warrants by the European Investment Bank

On January 17, 2024, the Company entered into an agreement with the European Investment Bank with its seat in Luxembourg ("EIB") for the subscription of series K subscription warrants ("Warrants"), under which the EIB subscribed for 592,825 (five hundred and ninety-two thousand eight hundred and twenty-five) Warrants, each of which entitles to subscribe for one series K share of the Company. The Warrants were taken up by the EIB free of charge. The National Depository for Securities (in Polish: Krajowy Depozyt Papierów Wartościowych S.A.) issued a statement on registration on February 1, 2024, in the securities depository of 592,825 (five hundred and ninety-two thousand eight hundred and twenty-five) series K subscription warrants under ISIN code PLSELVT00088.

Dosing of the first patient in the RIVER-81 Phase II study of RVU120 in combination with venetoclax

On January 31, 2024, the Company announced that the first patient had been dosed with the study drugs in a Phase II clinical trial investigating RVU120 in combination with venetoclax for the treatment of patients with relapsed/refractory acute myeloid leukemia (r/r AML)—the RIVER-81 study (NCT06191263). The Study is part of the RVU120 development plan (as reported above). Execution of the Study is supported with a PLN 62.3 million grant from the Polish Medical Research Agency (ABM).

Achievement of the second milestone under license agreement with Exelixis Inc.

On February 3, 2024, the Company has received a notice that the second milestone has been achieved in the research collaboration with Exelixis Inc. with its registered office in Alameda, California ("Exelixis") under the license agreement dated July 6, 2022 (the “Agreement”). The Agreement aims to develop novel targeted therapies using the STING (STimulator of INterferon Genes) technology developed by Ryvu. Based on the achievement of the milestone, Ryvu is entitled to receive a payment of USD 2 million (PLN 7 928 200 converted at the average exchange rate of the National Bank of Poland on February 2, 2024, 1 USD = 3.9641 PLN).

Dosing of the first patient in the RIVER-52 Phase II Study of RVU 120 as a monotherapy for the treatment of patients with relapsed/refractory AML and HR-MDS

On February 14, 2024, the Company announced that the first patient had been dosed with the study drug in a Phase II clinical trial investigating RVU120 as a monotherapy for the treatment of patients with relapsed/refractory acute myeloid leukemia (r/r AML) and high-risk myelodysplastic syndromes (HRMDS)—the RIVER-52 study. The Study is part of the RVU120 development plan (as reported above).

Fulfillment of conditions for the disbursement of the Tranche A of financing from the European Investment Bank

On March 5, 2024, the Company received from the European Investment Bank ("EBI") confirmation that the Company has fulfilled all conditions for the disbursement of the first tranche of financing ("Tranche A") under the financing agreement concluded on 16 August 2022. As a result, the Company expects to receive on March 13, 2024, an amount of EUR 8,000,000.00 (34,582,400.00 PLN converted at the average exchange rate of the National Bank of Poland on March 5, 2024, 1 EUR = 4.3228 PLN). The Company is obligated to repay Tranche A by March 13, 2029. After the disbursement of Tranche A, EBI will be entitled to (i) convert 215.575 subscription warrants (constituting 36,364% of all the 592.825 subscription warrants held by EBI) into 215.575 ordinary bearer shares of series K of the Company, (ii) dispose of the subscription warrants, (iii) require from the Company the purchase of the subscription warrants for their cancellation, all in accordance with the terms specified in the subscription warrant issuance agreement concluded on 4 May 2023.

Preclinical data on RVU120 and Synthetic Lethality Programs to be presented at the 2024 AACR Annual Meeting

On March 6, 2024, the Company announced that it will present preclinical data from its synthetic lethality pipeline and RVU120 project at the 2024 AACR Annual Meeting, which takes place April 5-10 in San Diego, California, USA. The poster presentations include updated preclinical data from Ryvu's synthetic lethality pipeline, including the PRMT5 program in MTAP-Deficient cancers, WRN inhibitors in the treatment of microsatellite unstable (MSI-H) tumors, and its cutting-edge synthetic lethality platform based on primary cancer cells. Furthermore, poster presentations highlight the synergistic effects of RVU120 in combination with ruxolitinib in myeloproliferative neoplasms. Also, during the 2024 AACR Annual Meeting data on SEL24 (MEN1703), demonstrating promising anti-tumor activity in preclinical models of myelofibrosis both as a single agent and combined with ruxolitinib will be presented by the Company's partner from Italian Menarini Group.

Ryvu project recommended for funding by the Polish Agency for Enterprise Development

On March 27, 2024, the Company informed that on March 25, 2024, it received an information about the inclusion by the Polish Agency for Enterprise Development ("PARP") of the Company's protest against the negative assessment of the Company's project under the name "ONCO Prime: new possibilities for personalized anticancer therapy based on patient-derived primary cell cultures, omics characterization and functional assays" ("Project") and the inclusion by PARP of the Company's Project on the updated list of projects recommended for funding under the SMART Track 1st call 2023 FENG.01.01-IP.02-001/23/2023, after the completed appeal procedure.

The ONCO Prime Project is a significant component in implementing the Company's plans in the early pipeline projects. The construction of a new platform for the discovery of innovative therapeutic targets using the unique patient-derived primary cancer cell cultures will open up entirely new possibilities for identifying new and unique protein targets, enriching Ryvu's early-stage oncology portfolio, molecular classification of patients, and drug testing within the framework of the Company's existing projects. The ONCO Prime platform will become a source of innovative cancer models with the highest translational potential containing disease history and histopathological, genomic and transcriptomic data. Additionally, it will enable the correlation of clinical and molecular data, supporting identifying patients sensitive to therapies developed by Ryvu.

- the total value of the Project (qualified costs): PLN 39 176 251.50;

- the recommended amount of funding for the Project: PLN 26 339 315.38;

- the start of the Project implementation: May 2023;

- maximum Project duration: 56 months.

If the funding agreement is concluded and the Project is implemented, the granted funding may limit the use of the Company's funds.

Conclusion of an agreement in the area of operational execution of RVU120 Phase II clinical trial in myelofibrosis

On March 28, 2024, the Company informed about the conclusion of an agreement with Fortrea Inc., headquartered in North Carolina, US ("Fortrea"), covering the operational execution of the POTAMI-61 clinical study ("Agreement"). The conclusion of the Agreement marks another step in the implementation of the RVU120 development plan ("Development Plan"), as announced by the Company in the current report 45/2023 on October 23, 2023.

The subject of the Agreement is the operational execution of the POTAMI-61 clinical study – a global, multicenter, Phase II study investigating RVU120 as a monotherapy and in combination with ruxolitinib for the treatment of patients with intermediate or high-risk, primary or secondary myelofibrosis. Services provided under the Agreement will encompass various aspects of clinical study execution, including clinical project management, medical and safety monitoring, as well as clinical site management and monitoring.

The POTAMI-61 study consists of two parts. Part A is designed to evaluate the safety and anti-tumor activity of RVU120 as a monotherapy and in combination with ruxolitinib in a group of approximately 20 patients. Based on the outcomes of Part A, Part B will further assess safety, tolerability, and anti-tumor activity in a larger cohort, totaling up to approx. 230 patients for both Part A and Part B combined.

Following the RVU120 Development Plan, the Management Board intends to proceed with the execution of Part A of the POTAMI-61 study, as described above. The estimated cost for all study start-up activities and the execution of Part A under the Agreement is approx. EUR 3 million. This includes all relevant services, as well as fees for investigators and clinical site-related procedures.

If the Management Board decides to proceed with Part B of the study (enrolling up to approximately 230 patients), the total value of the Agreement will amount to approximately EUR 16.4 million. Further decisions regarding prioritizations within the RVU120 Development Plan, including a decision on the potential initiation of Part B of the POTAMI-61 study, are scheduled to be made in Q1 2025.

The initiation of the POTAMI-61 study is scheduled for mid-2024.

B) EVENTS OCCURRED BETWEEN THE END OF REPORTING PERIOD UNTIL THE APPROVAL OF FINANCIAL STATEMENT

Posters on preclinical data on RVU120 and Synthetic Lethality Programs presented at the 2024 AACR Annual Meeting

On April 10, 2024, the Company informed that on April 9, 2024, during the the 2024 AACR Annual Meeting, Sand Diego, California, USA ("Conference") , the Company presented updated preclinical data from its synthetic lethality pipeline and RVU120. Moreover, on April 7, 2024, preclinical data on MEN1703 (SEL24) was presented by the Company's partner Menarini Group.

Updated information in relation to poster presentations about which the Company informed in the current report 11/2024 dated March 6, 2024 concerns:

- Company's PRMT5 program in MTAP-Deficient cancers showing that Ryvu PRMT5 inhibitors show potential best-in-class profiles, including a strong antiproliferative effect on MTAP-deleted cell lines and a good safety window versus MTAP WT cells.
- Ryvu's WRN inhibitors program has demonstrated target engagement and selective potency with a synthetic lethal effect; in vivo efficacy studies exhibited pronounced tumor growth inhibition in an MSI-H colorectal cancer xenograft model.
- Ryvu's proprietary ONCO Prime discovery platform, which recently has been recommended for funding of PLN 26 million (approx. USD 6.6 million) by the Polish Agency for Enterprise Development as announced by the Company in the current report 14/2024 on March 27, 2024, has identified novel drug targets in KRAS-mutant patient-derived cells (PDCs) with therapeutic potential in colorectal cancer; the ONCO Prime platform has broad potential across multiple tumor types.
- MEN1703 (SEL24), presented by the Company's partner Menarini Group, shows cytotoxic activity in myelofibrosis cell lines as monotherapy and synergistically in combination with ruxolitinib.

2.3 Unusual events occurring in the reporting period

Conflict in Ukraine

Due to the Ukraine conflict outbreak, the Issuer's Management Board has analyzed the potential impact of the ongoing war on the Issuer's operations. In the opinion of the Management Board, apart from the currency risk, the Management Board did not identify any other significant risks that could affect the Issuer's operations.

In particular, it should be noted that the Issuer has no assets in Ukraine and does not conduct business and operations in Ukraine and Russia. The share of entities from Ukraine or Russia as suppliers in the Issuer's structure remains insignificant and is mostly limited to the provision of compound libraries for discovery stage projects at their early stage.

Nevertheless, the Company's Management Board analyzes the Issuer's situation on an ongoing basis. Any new circumstances that significantly impact the issuer's financial results and business situation will be communicated to investors.

3. THE ISSUER'S CORPORATE BODIES

Issuer's Management Board:

1) Paweł Przewięźlikowski – President of the Management Board
2) Krzysztof Brzózka – Vice President of the Management Board
3) Kamil Sitarz – Member of the Management Board
4) Vatnak Vat-Ho – Member of the Management Board
5) Hendrik Nogai – Member of the Management Board

Issuer's Supervisory Board :

1) Piotr Romanowski – Chairman of the Supervisory Board
2) Tadeusz Wesołowski – Vice Chairman of the Supervisory Board
3) Rafał Chwast – Supervisory Board Member
4) Axel Glasmacher – Supervisory Board Member
5) Jarl Ulf Jungnelius – Supervisory Board Member*
6) Thomas Turalski – Supervisory Board Member
7) Scott Z. Fields – Supervisory Board Member
8) Peter Smith – Supervisory Board Member

** Mr. Jarl Ulf Jungnelius resigned from the position of a member of the Supervisory Board, effective January 3, 2024*

Issuer's Audit Committee:

1) Rafał Chwast – Chairman of the Audit Committee
2) Piotr Romanowski – Member of the Audit Committee
3) Tadeusz Wesołowski – Member of the Audit Committee
4) Jarl Ulf Jungnelius – Member of the Audit Committee*

** Mr. Jarl Ulf Jungnelius resigned from the position of a member of the Supervisory Board, effective January 3, 2024.*

The Company's Remuneration Committee:

1) Piotr Romanowski – Chairman of the Remuneration Committee
2) Axel Glasmacher – Member of the Remuneration Committee
3) Thomas Turalski – Member of the Remuneration Committee

4. INFORMATION ON THE SHAREHOLDERS HOLDING (DIRECTLY OR INDIRECTLY) AT LEAST 5% OF THE TOTAL NUMBER OF VOTES AT THE GENERAL SHAREHOLDERS' MEETING OF THE COMPANY AND ON SHARES HELD BY MEMBERS OF THE ISSUER'S MANAGEMENT BOARD AND SUPERVISORY BOARD

Shares held by members of the Management and Supervisory Board of the Company as of 31.03.2024

Shareholder	Preferred shares*	Ordinary shares	Number of shares	% of Share Capital	Number of Votes	% of Votes at SM
Paweł Przewięźlikowski	3 500 000	533 286	**4 033 286**	17.44%	**7 533 286**	27.73%
Krzysztof Brzózka		267 321	**267 321**	1.16%	**267 321**	0.98%
Kamil Sitarz		39 230	**39 230**	0.17%	**39 230**	0.14%
Vatnak Vat-Ho		42 750	**42 750**	0.18%	**42 750**	0.16%
Hendrik Nogai		13 500	**13 500**	0.06%	**13 500**	0.05%
Tadeusz Wesołowski (directly)		92 975	**92 975**	0.40%	**92 975**	0.34%
Tadeusz Wesołowski (indirectly through Augebit FIZ)**		1 279 738	**1 279 738**	5.54%	**1 279 738**	4.71%
Rafał Chwast		121 115	**121 115**	0.52%	**121 115**	0.45%
Thomas Turalski		20 100	**20 100**	0.09%	**20 100**	0.07%

**A single Series A share entitles to two votes at the Shareholder Meeting.*
***The beneficiary of Augebit FIZ is Tadeusz Wesołowski - Vice-Chairman of the Issuer's Supervisory Board*

Shares held by members of the Management and Supervisory Board of the Company as of the date of Report publication

Imię i nazwisko akcjonariusza	Akcje uprzywilejowane*	Akcje zwykłe	Suma akcji	% kapitału zakładowego	Suma głosów	% głosów na WZ
Zarząd						
Paweł Przewięźlikowski	3 500 000	533 286	**4 033 286**	17.44%	**7 639 544**	27.73%
Krzysztof Brzózka		267 321	**267 321**	1.16%	**267 321**	0.98%
Kamil Sitarz		39 230	**39 230**	0.17%	**39 230**	0.14%
Vatnak Vat-Ho		42 750	**42 750**	0.18%	**42 750**	0.16%
Hendrik Nogai		13 500	**13 500**	0.06%	**13 500**	0.05%
Rada Nadzorcza						
Tadeusz Wesołowski (bezpośrednio)		92 975	**92 975**	0.40%	**92 975**	0.34%
Tadeusz Wesołowski (przez Augebit FIZ)**		1 279 738	**1 279 738**	5.54%	**1 279 738**	4.71%
Piotr Romanowski		100 000	**100 000**	0.43%	**100 000**	0.37%

Rafał Chwast	121 115	**121 115**	0.52%	**121 115**	0.45%
Thomas Turalski	20 100	**20 100**	0.09%	**20 100**	0.07%

**A single Series A share entitles to two votes at the Shareholder Meeting.*
***The beneficiary of Augebit FIZ is Tadeusz Wesołowski - Vice-Chairman of the Issuer's Supervisory Board*

Shares held by significant shareholders of the Company as of 31.03.2024 and as of the date of Report publication

Shareholder	Shares	% [Shares]	Votes	% [Votes]
Paweł Przewięźlikowski	4 033 286	17.44%	7 533 286	27.73%
Bogusław Sieczkowski	825 348	3.57%	1 375 348	5.06%
Tadeusz Wesołowski (with Augebit FIZ*)	1 372 713	5.94%	1 372 713	5.05%
Nationale Nederlanden OFE	1 900 000	8.22%	1 900 000	6.99%
Allianz Polska OFE	2 132 000	9.22%	2 132 000	7.85%
TFI Allianz Polska S.A.	1 910 236	8.26%	1 910 236	7.03%
BioNTech SE	1 917 437	8.29%	1 917 437	7.06%

The above information on the state of possession of the Issuer's shares by shareholders (including those being members of the Company's bodies) holding directly and indirectly at least 5% of the total number of votes at the Company's General Meeting has been prepared on the basis of information obtained from shareholders through their performance of duties imposed on shareholders of public companies by virtue of relevant legal regulations, including on the basis of the provisions of the Act of 29. July 2005 on public offering and the conditions for introducing financial instruments to the organized trading system and on public companies (art. 69 and art. 69a) and on the basis of the provisions of the Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse and repealing Directive 2003/6/EC of the European Parliament and of the Council and Commission Directive 2003/124/EC, 2003/125/EC and 2004/72/EC (MAR Regulation, art. 19). In addition, information on the ownership of the Company's shares is provided on the basis of publicly available data on the portfolio exposure and asset structure of investment funds or pension funds, including information on the number of shares registered at the Company's General Meeting (data available periodically, inter alia, based on information from the financial statements of investment funds and pension funds - data may be subject to change since the date of publication of the last information).

5. STATEMENT OF THE MANAGEMENT BOARD REGARDING APPLICABLE ACCOUNTING PRINCIPLES

The Management Board of Ryvu Therapeutics S.A. confirms that, to the best of its knowledge, the financial statements have been prepared in accordance with the applicable accounting principles and reflect in a true, reliable and clear manner the financial situation of Ryvu Therapeutics S.A. and its financial results. Report of the Management Board on the activities of Ryvu Therapeutics S.A. contains a true picture of the development and achievements, including a description of the basic threats and risks.

6. ADDITIONAL INFORMATION

Proceedings pending at court, before an arbitration institution or a public administration authority

The Company has filed a lawsuit against Mota-Engil Central Europe S.A. ("Contractor") to the Regional Court in Kraków concerning the construction of the Research and Development Center under the agreement for "Construction of the Research and Development Center of Innovative Drugs Selvita S.A." dated August 13, 2018 ("Construction Agreement"). The claims include the payment of contractual penalties for failure to meet the final deadline, and intermediate deadlines, as well as for rectification or untimely reflection of defects in relation to the scope of the Construction Agreement, totaling the amount of PLN 13,756,717.07. The total value of the Construction Agreement was PLN 68.783.585,34 including VAT. The proceedings are taking place before the District Court in Krakow in the first instance – witness testimonies are currently being heard.

The Contractor has filed a lawsuit for payment against the Company to the Regional Court in Kraków in connection with the performance of the Construction Agreement for the project entitled: "Construction of the Research and Development Center for Innovative Drugs Selvita S.A." In the lawsuit the Contractor is claiming damages for the costs incurred in connection with prolonged performance of the Construction Agreement, the unpaid portion of the lump sum fee as well as supplementary remuneration for additional, replacement and omitted works (PLN 5,391,425.63) as well as damages resulting from the Company's unauthorized - in the Contractor's opinion - application of the performance bond and removal of the defects and faults (PLN 2,063,507.56). With the statutory interests, the Contractor demands a total amount of PLN 7,671,285 from the Company. On 22.11.2023, the hearings of all witnesses and parties were completed. The case files have been sent to a court-appointed expert, who will prepare an opinion based on the specified questions.

Significant non-arms length transactions with related entities

Not applicable.

Information on organizational or capital relations of the Issuer with other entities

As at the report's publication date, the Issuer does not form a Capital Group. As at the date of this Report, the Issuer holds 2.38% of shares in NodThera Inc.

Warranties for loans and borrowings and guarantees granted

Not applicable.

Other information significant for the assessment of the Issuer's position in the area of human resources, assets, cash flows, financial results and changes thereof and information significant for the assessment of the Issuer's ability to settle its liabilities

Not applicable.

Factors which, in the Issuer's opinion, will affect the results over at least the following quarter

The results of the subsequent quarters will depend primarily on the execution of the Company's strategy, which assumes in particular that the following business objectives will be met:

- Completing the ongoing Phase I clinical studies of RVU120 in AML/HR-MDS and solid tumors;
- Expanding therapeutic potential of RVU120 by initiating broad Phase II clinical development across multiple indications (hematology and solid tumors) and in diverse treatment settings (monotherapy and combination therapy);
- Supporting clinical development of our partnered candidate, SEL24 (MEN1703) by Menarini Group;
- Conducting preclinical development and advancing into Phase I clinical trials of one new program;
- Strengthening of our Synthetic Lethality Platform and accelerating progress in the early pipeline;
- Achieving financial milestones in the existing R&D collaborations (i.e. BioNTech, Exelixis, Menarini);
- Signing at least one new partnering agreement per year.

Explanations regarding the seasonal or cyclical nature of the Issuer's operations in the reported period

Not applicable.

Information on inventory write-downs to the net realizable amount and reversal of such write-downs

Not applicable.

Information on impairment write-downs in respect of financial assets, tangible fixed assets, intangible assets or other assets and the reversal of such write-downs

Not applicable.

Information on the set-up, increase, utilization and reversal of provisions

Information on the changes in provisions for holidays and bonuses is provided in note 17 to the financial statements.

Information on deferred income tax provisions and assets

No significant changes.

Information on significant purchases or disposals of tangible fixed assets

No significant changes.

Information on significant liabilities in respect of purchases of tangible fixed assets

No significant changes.

Information on significant settlements resulting from court cases

Not applicable.

Error corrections relating to previous periods

Not applicable.

Information on changes in the economic situation and business conditions, which have a significant effect on the fair value of the entity's financial assets and financial liabilities

Not applicable.

Information on the failure to repay a loan or borrowing or a breach of significant terms and conditions of a loan agreement, with respect to which no corrective action had been taken by the end of the reporting period

Not applicable.

Information on changes in the method of valuation of financial instruments measured at the fair value

Not applicable.

Information on changes in the classification of financial assets due to a change in their purpose

Not applicable.

Information on the issue, redemption and repayment of non-equity and equity securities

Not applicable.

Information on dividends paid (or declared) in the total amount and per share, divided into ordinary and preference shares

Not applicable.

Events that occurred after the date for which the quarterly financial statements were prepared, not disclosed in these financial statements although they may have a significant effect on the Issuer's future financial results

Not applicable.

Information on changes in contingent liabilities or contingent assets that occurred after the end of the last financial year

Information on changes in contingent liabilities or contingent assets is provided in note 22 to the financial statements.

Other disclosures which may have a material impact on the assessment of the Issuer's financial position and results of operations

Not applicable.

Amounts and types of items affecting the assets, liabilities, equity, net profit/ (loss) or cash flows, which are unusual in terms of type, amount or frequency

Not applicable.

Krakow, May 14, 2024

Dokument podpisany przez Paweł Tadeusz Przewięźlikowski
Data: 2024.05.14 13:14:44 CEST

Paweł Przewięźlikowski
President of the Management Board

Dokument podpisany przez Krzysztof Daniel Brzózka
Data: 2024.05.14 11:44:58 CEST

Krzysztof Brzózka
Vice-President of the Management Board

Dokument podpisany przez Kamil Sitarz
Data: 2024.05.14 11:05:27 CEST

Kamil Sitarz
Management Board Member

Digitally signed by Vatnak Vat-Ho
Date: 2024.05.14 09:46:53 MDT

Vatnak Vat-Ho
Management Board Member

Signed by / Podpisano przez:
FRANZ HENDRIK DR. NOGAI
Date / Data: 2024-05-14 11:22

Hendrik Nogai
Management Board Member

CONTACT

RYVU THERAPEUTICS

2 Sternbacha Street

30-394 Krakow, Poland

P: +48 12 314 02 00

GENERAL INQUIRIES

ryvu@ryvu.com

RYVU THERAPEUTICS